- In December 2024, Ellab completed the acquisition of PharmaProcess in Italy and Switzerland, aimed at strengthening its life science service portfolio. The integration combines PharmaProcess' regulatory knowledge with Ellab’s compliance solutions, enabling comprehensive support for pharmaceutical and biotechnology companies across both countries. This move is expected to expand Ellab’s regional footprint and enhance service capabilities for endotoxin and quality testing requirements
- In September 2024, Lonza Walkersville initiated the expansion of its endotoxin assay production site in Walkersville, Maryland, with an 18,000-square-foot facility upgrade. This expansion is designed to increase production capacity in response to the growing global demand for endotoxin assays essential for ensuring the safety of injectable drugs and medical devices. The development will further strengthen Lonza’s position in the LAL Testing market
- In June 2024, FUJIFILM Wako Pure Chemicals unveiled two advanced endotoxin and pyrogen detection solutions: the LumiMAT Pyrogen Detection Kit, a next-generation monocyte activation test, and PYROSTAR Neo+, a recombinant protein reagent for bacterial endotoxin testing, which became globally available in July 2024. These innovations enhance the accuracy and efficiency of endotoxin detection, supporting safety standards across pharmaceutical and medical applications
- In March 2024, AmeboGenesis achieved a significant breakthrough in sustainable Amebocyte production by introducing a pioneering technology that enables the laboratory production of bio-identical Amebocytes for LAL testing, eliminating the need to harvest horseshoe crab blood. As horseshoe crab blood is critical for Limulus Amebocyte Lysate (LAL) production, this advancement promotes sustainability while ensuring the safety of injectable drugs, vaccines, and medical devices worldwide
- In October 2023, Lonza launched two Monocyte Activation Test (MAT) systems, the PyroCell MAT Human Serum (HS) Rapid System and the PyroCell MAT Rapid System, designed to deliver faster, reliable pyrogen testing for pharmaceutical manufacturers. These systems enhance efficiency in detecting pyrogens, contributing to improved safety and regulatory compliance in drug and medical device production processes
